EXACT Sciences Corporation

EXACT Sciences — Investor Day (June 2023)

128 slides from EXACT Sciences's investor day presentation, Jun 21, 2023

  1. Slide 1: We aim to eradicate cancer

    June 21, 2023 We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment. EXACT SCIENCES

  2. Slide 2: Safe harbor and non-GAAP disclosures

    This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and u

  3. Slide 3: Today's agenda

    Today’s agenda Jake Orville GM, SCREENING Jorge Garces CHIEF SCIENCE OFFICER Brian Baranick GM, PRECISION ONCOLOGY Sarah Condella EVP, HUMAN RESOURCES Everett Cunningham CHIEF COMMERCIAL OFFICER Jeff Elliott EVP, CHIEF FINANCIAL OFFICER Kevin Conroy CHAIRMAN AND CEO 10:00 am Welcome and opening Kevi

  4. Slide 4: 4EXACT SCIENCES 4EXACT

    4EXACT SCIENCES 4EXACT SCIENCES

  5. Slide 5: Kevin Conroy, Chairman and CEO

    Kevin Conroy Chairman and CEO We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment. EXACT SCIENCES 5

  6. Slide 6: Our core values are embedded in everything we do

    Innovation Accountability Our core values are embedded in everything we do IntegrityTeamworkQuality 6EXACT SCIENCES

  7. Slide 7: Leadership expectations and behaviors

    LEADERSHIP EXPECTATIONS AND BEHAVIORS T ne team approach puts team ahead of self eeks and acts on feedback Celebrates success and frames failure as progress Acts on curiosity and al ays learning Acts like an o ner makes decisions and moves uickly Takes personal accountability to deliver uality resul

  8. Slide 8: Strategic priorities

    Provide a seamless experience for customers Invest in world-class talent dedicated to fighting cancer Offer tests that impact decision-making Increase access & drive adoption Generate rock-solid clinical evidence Drive profitable revenue 8EXACT SCIENCES

  9. Slide 9: Progress towards eradicating cancer

    TOP-LINE BLUE-C RESULTS VISIONARY COLLABORATIONS Progress towards eradicating cancer EXACT SCIENCES 9

  10. Slide 10: A new standard in non-invasive screening

    next-generation A new standard in non-invasive screening 10EXACT SCIENCES

  11. Slide 11: Next-generation Cologuard vs DeeP-C

    next-generation 90% specificity including no findings 92% cancer sensitivity 69% high-grade dysplasia sensitivity 42% advanced precancer sensitivity DeeP-C 93% specificity including no findings 94% cancer sensitivity 75% high-grade dysplasia sensitivity 43% advanced precancer sensitivity BLUE-C Sour

  12. Slide 12: How we help detect cancer earlier and provide smarter answers

    MRD & recurrence Prognosis & prediction Hereditary testing Screening & diagnosis Early-stage therapy expected 2023 How we help detect cancer earlier and provide smarter answers at every step multi-cancer liver, esophageal, & others Includes tests in development, which are not available for sale or a

  13. Slide 13: 13EXACT

    13 13EXACT SCIENCES

  14. Slide 14: Invest in world-class talent

    Sarah Condella EVP, Human Resources Invest in world-class talent 1414EXACT SCIENCES

  15. Slide 15: Strategic priorities

    Provide a seamless experience for customers Invest in world-class talent dedicated to fighting cancer Offer tests that impact decision-making Increase access & drive adoption Generate rock-solid clinical evidence Drive profitable revenue 15 EXACT SCIENCES

  16. Slide 16: 16EXACT

    16EXACT SCIENCES

  17. Slide 17: The driving force behind our flywheel is our team

    6,300+ teammates dedicated to defeating cancer 100% of teammates are shareholders 54% gender diversity The driving force behind our flywheel is our team 40+ locations globally in 18 cities Source: Exact Sciences internal data 17 EXACT SCIENCES

  18. Slide 18: Attract, develop, retain

    ATTRACT DEVELOP RETAIN 1818EXACT SCIENCES

  19. Slide 19: Our culture attracts the best talent

    2017 2018 2019 2020 2021 2022 1Q23 23K+ AVERAGE # OF QUARTERLY JOB APPLICATIONS Our magnetic, purpose-driven culture attracts the best talent Source: Exact Sciences internal data ATTRACT 19EXACT SCIENCES

  20. Slide 20: Creating a more sustainable, cancer-free world

    Creating a more sustainable, cancer-free world for future generations 20 ATTRACT AND HIRE ATTRACT EXACT SCIENCES

  21. Slide 21: Developing and promoting career growth

    330K annual training hours 80%+ of teammates participate in wellness program 2 in 5 teammates enrolled in mentorship program Developing and promoting career growth is key to our success EXACT SCIENCES Source: Exact Sciences internal data 21 DEVELOP & GROW DEVELOP

  22. Slide 22: Fostering innovation through engagement

    Fostering innovation through engagement Best Workplaces in BiopharmaTM Best-in-State Employer GREAT PLACE TO WORK RESULTS 82% 57% Typical company Source: Exact Sciences internal data RETAIN 22EXACT SCIENCES

  23. Slide 23: Changing lives, together

    Changing lives, together 23EXACT SCIENCES

  24. Slide 24: Develop tests that impact decisions

    Jorge Garces Chief Science Officer Develop tests that impact decisions 2424EXACT SCIENCES

  25. Slide 25: Strategic priorities

    Provide a seamless experience for customers Invest in world-class talent dedicated to fighting cancer Offer tests that impact decision-making Increase access & drive adoption Generate rock-solid clinical evidence Drive profitable revenue 25EXACT SCIENCES

  26. Slide 26: R&D capacity and team

    OUR CAPACITY 100K+ square feet of operational R&D lab space 4 R&D centers globally OUR TEAM 285 scientists 110 PhDs in R&D Broad scientific capabilities & leadership Source: Exact Sciences internal data 26EXACT SCIENCES

  27. Slide 27: Methodical approach to product and evidence development

    Research & development Approval Adoption & access Sample & data collection discovery, evaluation, feasibility, development, proof of concept Analytical performance sensitivity, specificity, precision, repeatability, reproducibility, limits of detection Clinical performance & safety sensitivity, spec

  28. Slide 28: Multi-omics is the answer

    Multi-omics is the answer San Diego, CA Transcriptomics (RNA) Madison, WI Munich, Germany Proteomics (Proteins) Madison, WI San Diego, CA Boston, MA Genomics (DNA) 28EXACT SCIENCES

  29. Slide 29: Unmatched marker discovery capabilities: methylation

    Lung Liver Stomach Colon Bile duct Esophagus Prostate Pancreas Sample acquisition Whole methylome sequencing Marker selection Marker refinement Marker testing in tissue and plasma Refining assays and finalizing markers Methylation Unmatched marker discovery capabilities Breast Ovary Lymphoma Uterus

  30. Slide 30: Marker selection process

    30 Validate in blood, stool, other Marker selection process Methylation Unmatched marker discovery capabilities Discover markers in tissue Source: Marinelli et al., Gyn Onc, 2022; Chiesa et al., BMC BIX, 2020 F Dataset Learning dataset Independent test set Training set Validation set Feature selecti

  31. Slide 31: Unmatched marker discovery: mutations

    Mutations Unmatched marker discovery capabilities 31EXACT SCIENCES

  32. Slide 32: Unmatched marker discovery: proteins

    Proteins Unmatched marker discovery capabilities Protein Discovery Platform Assay Platform Thousands of proteins and phosphopeptides 1 cancer sample Source: Exact Sciences internal data Sample preparation Liquid chromatography Mass spectrometry Spectra interpretation Protein quantification Data anal

  33. Slide 33: Expertise across technologies with an automated platform

    Expertise across technologies with an automated platform SANGER SEQUENCING HIGH-THROUGHPUT NGS PRODUCTION-SCALE NGS Sequencing power for all applications with 60 platforms Source: Exact Sciences internal data 26K transcriptomes sequenced 2.6K genomes sequenced 247K exomes sequenced 33EXACT SCIENCES

  34. Slide 34: SaferSeqS and RealSeqS

    Expertise across technologies with an automated platform SaferSeqS & RealSeqS Safer Sequencing System & Repetitive Element AneupLoidy Sequencing System Exact Sciences maintains exclusive rights Detects variants at frequencies below 1 in 100K DNA molecules Reduces the error rate of existing PCR-based

  35. Slide 35: TELQAS chemistry

    Expertise across technologies with an automated platform TELQASTM Chemistry Target Enrichment Long probe Quantitative Amplified Signal Developed and owned by Exact Sciences Single copy detection Faster time to result Multiplex PCR 12 cycles 4,096-fold amplification LQAS Limited sample 0 20 40 60 80

  36. Slide 36: Exact Sciences is technology agnostic

    300 Hamilton liquid handlers 130 Real-time ABI 7500 systems 60 Sequencers Source: Exact Sciences internal data Exact Sciences is technology agnostic Expertise across technologies with an automated platform 36EXACT SCIENCES

  37. Slide 37: LBgard blood collection tubes

    Expertise across technologies with an automated platform LBgard® Proprietary technology increases yield and decreases contamination 109% increase in plasma recovery yield 52% decrease in gDNA contamination Source: Dodson G et al., Advances in Liquid Biopsy: LBgard® Blood Tubes for Multi-omic Testing

  38. Slide 38: Bioinformatics proficiency

    38 Proficiency optimizing comprehensive algorithmstraining sets cross validation validation sets independent test sets artificial neural networks multi-marker approach proprietary chemistry machine learning classifier 70 person bioinformatics team 38EXACT SCIENCES

  39. Slide 39: Strong intellectual property portfolio

    900+ patents issued worldwide 400+ patent applications filed Strong intellectual property portfolio protects unique advantages Source: Exact Sciences internal data 39EXACT SCIENCES

  40. Slide 40: Offer tests that impact decisions

    Jake Orville General Manager, Screening Offer tests that impact decisions 40EXACT SCIENCES

  41. Slide 41: How we help detect cancer earlier

    MRD & recurrence Prognosis & prediction Hereditary testing Screening & diagnosis Early-stage therapy expected 2023 How we help detect cancer earlier and provide smarter answers at every step multi-cancer liver, esophageal, & others Includes tests in development, which are not available for sale or a

  42. Slide 42: Providing the best screening tests

    Therapy selection & monitoring MRD & recurrence Prognosis & prediction Hereditary testing Screening & diagnosis Early-stage therapy expected 2023 Providing the best screening tests to help prevent and detect cancer earlier multi-cancer liver, esophageal, & others Includes tests in development, which

  43. Slide 43: Colorectal cancer: 60M unscreened Americans

    unscreened Americans ages 45-85 60M Diagnosed in stage IV 1 out of 10 survive Source: Fisher D et al., ASCO Gastrointestinal Cancers Symposium (2022); Exact Sciences estimates based on 51% screening rate for ages 50-85 and 10-15% screening rate for ages 45-49; Siegel RL et al., Cancer Statistics (20

  44. Slide 44: Colorectal cancer: easy-to-use, non-invasive test

    No sedation No time off work No preparation 94% 91% Easy to use Non-invasive 24/7 support Source: Imperiale TF et al., N Engl J Med (2014); Siegel RL et al., Cancer Statistics (2022); Exact Sciences internal data Diagnosed in stages I & II 9 out of 10 survive COLORECTAL CANCER 92% 87% specificitycan

  45. Slide 45: Colorectal cancer screening milestones

    2013 2015 2017 2019 2021 Announced DeeP-C results Apr Medicare Stars Apr ~90% insurance coverage Jul 2M people screened Feb 2023 2025 2027 30M+ expected people screened 2012 2014 2016 2018 2020 2022 Completed DeeP-C enrollment Nov FDA approval Aug Medicare NCD Oct USPSTF guidelines Jun HEDIS measure

  46. Slide 46: Expected people screened by 2027

    expected people screened by 2027 35M+ expected people screened by 2027 COLORECTAL CANCER 46EXACT SCIENCES

  47. Slide 47: Options and services

    A test and services Options and services COLORECTAL CANCER 47EXACT SCIENCES

  48. Slide 48: Multi-cancer: 70% of cancers have no screening options

    70% of cancers have no SCREENING OPTIONS Source: United States Preventive Services Task Force. A and B recommendations (2022); Siegel RL et al., A. Cancer Statistics (2021); Siegel DA et al., JAMA Oncol. (2021); Richards TB et al. Morb Mortal Wkly Rep. (2020); American Cancer Society statistics on a

  49. Slide 49: Multi-cancer: 135M Americans ages 45-85

    Americans ages 45-85 135M Source: U.S. Census data; American Cancer Society statistics on average 5-year relative survival rates for 19 leading cancers Diagnosed in stage I 8 out of 10 survive MULTI-CANCER 49EXACT SCIENCES

  50. Slide 50: Adding mutation to methylation improves accuracy

    35% improvement in early-stage sensitivity 29% 3 marker classes 39% 4 marker classes Adding mutation to methylation improves accuracy DETECT-A The first prospective study 10K asymptomatic people Doubled cancers found compared to SOC alone 2/3 were earlier stages Source: Lennon AM et al., Science (20

  51. Slide 51: Multi-cancer next steps

    Refine clinical implementation practices Generate real-world evidence Optimize ordering workflow MULTI-CANCER 51EXACT SCIENCES

  52. Slide 52: Exact Sciences acquires Thrive

    TO CREATE TM BUILT ON THE FOUNDATION CREATED BY EXACT SCIENCES ACQUIRES THRIVE 52EXACT SCIENCES

  53. Slide 53: How we help detect cancer earlier

    MRD & recurrence Prognosis & prediction Hereditary testing Screening & diagnosis Early-stage therapy expected 2023 How we help detect cancer earlier and provide smarter answers at every step liver, esophageal, & others Includes tests in development, which are not available for sale or approved by FD

  54. Slide 54: Offer tests that impact decisions

    Brian Baranick General Manager, Precision Oncology Offer tests that impact decisions 54EXACT SCIENCES

  55. Slide 55: Enabling personalized medicine through Precision Oncology

    MRD & recurrence Prognosis & prediction Hereditary testing Screening & diagnosis Early-stage therapy expected 2023 Enabling personalized medicine through our Precision Oncology portfolio liver, esophageal, & others Includes tests in development, which are not available for sale or approved by FDA 55

  56. Slide 56: Katie Couric video

    56 KATIE COURIC VIDEO https://exactsciences.app.box.com/s/z od7dxyokb5iyeanxe4t2rrn841nnkoi 56EXACT SCIENCES

  57. Slide 57: Oncotype DX established a new standard

    ~1M U.S. patients spared unnecessary chemotherapy Oncotype DX established a new standard in personalized cancer care ~1.2M cumulative U.S. patients tested $400M+ U.S. revenue 80%+ U.S. market penetration Source: Sparano et al., N Engl J Med (2018); Geyer et al., NPJ Breast Cancer (2018); Exact Scien

  58. Slide 58: Oncotype DX supported by unmatched evidence

    Oncotype DX is supported by unmatched evidence and all major guidelines Range: 0-100 ASCO® NCCN® ESMO ST. GALLEN NICE 100K+ patients with published prospective outcomes TAILORx 10K women, 12 years RxPONDER 5K women, 5 years Source: Sparano et al., N Engl J Med (2018); Geyer et al., NPJ Breast Cancer

  59. Slide 59: International Precision Oncology footprint

    Oncotype DX provides an international Precision Oncology footprint Solidify standard of care in established markets Increase adoption in growing markets Launch in new markets 110 sales team members 120 country presence + Source: Exact Sciences internal data 59EXACT SCIENCES

  60. Slide 60: Unique advantages in Precision Oncology

    Our platform provides unique advantages in Precision Oncology Commercial channel Relationships with 90%+ of oncologists Tissue access ~200K samples each year EMR platform Seamless ordering and resulting Logistics capabilities Experience with complex workflows Lab operations excellence Automation ena

  61. Slide 61: MRD: hybrid capture technology

    Hybrid capture technology Targets and captures specific DNA fragments Proprietary detection algorithm Operationally reliable Superior LBgard® collection tubes 61EXACT SCIENCES

  62. Slide 62: MRD: whole genome technology

    Whole genome technology Expanded breadth of mutations Attractive cost profile 62EXACT SCIENCES

  63. Slide 63: Universal MRD platform opportunities

    EXACT SCIENCES Second largest opportunity Established evidence & reimbursement Synergies with Cologuard Largest opportunity Demonstrate clinical utility through partnerships Significant synergies with Oncotype DX Universal MRD platform Tumor-informed and -agnostic approaches Synergies with Cancergua

  64. Slide 64: Ultra-comprehensive genomic profiling

    Providing ultra-comprehensive genomic profiling, including DNA and RNA 20,000 genes ~325 20,000+ targets ~50 OncoExTraOther tests DNA (tumor + inherited) RNA Protein Source: Exact Sciences internal data 64EXACT SCIENCES

  65. Slide 65: Patient journey: hereditary cancer

    HEREDITARY CANCER MRD BASELINE MRD SURVEILLANCE MRD SURVEILLANCE MRD SURVEILLANCE RS result + - + - 48 + - + - + - Selena, a colorectal cancer patient Illustrative example, not a real patient + - 65 EXACT SCIENCES

  66. Slide 66: Patient journey: screening

    MRD BASELINE MRD SURVEILLANCE MRD SURVEILLANCE MRD SURVEILLANCE RS result + - 48 + - + - + - Selena, a colorectal cancer patient SCREENING + - + - Illustrative example, not a real patient 66 EXACT SCIENCES

  67. Slide 67: Patient journey: early-stage cancer

    MRD BASELINE MRD SURVEILLANCE MRD SURVEILLANCE MRD SURVEILLANCE RS result + - 48 + - + - + - Selena, a colorectal cancer patient EARLY-STAGE CANCER + - -+ Illustrative example, not a real patient 67 EXACT SCIENCES

  68. Slide 68: Patient journey: recurrence testing

    MRD BASELINE MRD SURVEILLANCE MRD SURVEILLANCE MRD SURVEILLANCE RS result + - 48 + - + - + - Selena, a colorectal cancer patient RECURRENCE TESTING + - -+ Illustrative example, not a real patient 68 EXACT SCIENCES

  69. Slide 69: Patient journey: relapse

    MRD BASELINE MRD SURVEILLANCE MRD SURVEILLANCE MRD SURVEILLANCE RS result + - 48 + - + - + - Selena, a colorectal cancer patient RELAPSE + - -+ 69 Illustrative example, not a real patientEXACT SCIENCES

  70. Slide 70: Generate rock-solid evidence

    Jorge Garces Chief Science Officer Generate rock- solid evidence 707EXACT SCIENCES

  71. Slide 71: Strategic priorities

    Provide a seamless experience for customers Invest in world-class talent dedicated to fighting cancer Offer tests that impact decision-making Increase access & drive adoption Generate rock-solid clinical evidence Drive profitable revenue 71EXACT SCIENCES

  72. Slide 72: Generating evidence the xact way

    Generating evidence “the xact way” Clinical trials definitively establishing test performance Real-world evidence and long-term outcomes supporting test use Modeling studies demonstrating population impact 727EXACT SCIENCES

  73. Slide 73: NEJM publications

    73 6 NEJM publications Exact Sciences conducts studies that make a difference over the long term 10K 5K 10K 10K 20KBLUE-C TAILOR-X RxPONDER DeeP-C DETECT-A Source: Sparano JA et al., N Engl J Med (2018); Kalinsky K et al., N Engl J Med (2021); Imperiale TF et al., N Engl J Med (2014); Paik S et al.,

  74. Slide 74: Access to more than 1.1M high-quality samples

    439K 271K 186K 116K 69K 10K 9K 1K Plasma Stool Buffy coat Serum Tissue Cell pellet Blood Urine Aliquots in storage by sample type 100+ Clinical Affairs team members 275+ completed/ongoing clinical studies 292K+ cumulative people enrolled We have access to more than 1.1M high-quality samples Source:

  75. Slide 75: BLUE-C clinical trial results

    next-generation BLUE-C Source: Exact Sciences internal data; Imperiale TF et al., N Engl J Med (2014) 94% cancer sensitivity 91% specificity including non- advanced findings CLINICAL TRIALS Category, n (%) BLUE-C (n=20,208) DeeP-C (n=9,989) Colorectal cancer 98 (0.48) 65 (0.65) Advanced pre- cancero

  76. Slide 76: DETECT-A real-world evidence

    DETECT-A Source: Buchannan A et al., ASCO (2023); Lennon A et al., ASCO (2023) 100% 86% of early-stage diagnosed and treated patients still living cancer free of surgically-treated patients in remission <1% of false-positive results developed cancer annually over 4 years REAL-WORLD EVIDENCE 76EXACT

  77. Slide 77: Oncotype DX real-world evidence

    90K patients with invasive breast cancer 9 years of follow up Source: Geyer C et al., ASCO abstract (2023) SEER data Confirmed Oncotype DX was prognostic for breast cancer-specific mortality REAL-WORLD EVIDENCE 77EXACT SCIENCES

  78. Slide 78: Modeling studies

    100+ health economic studies in the last 3 years 40K+ scenarios simulated 21K lines of code in one colorectal cancer model Source: Exact Sciences internal data MODELING STUDIES 78EXACT SCIENCES

  79. Slide 79: cologuard®

    cologuard® EXACT SCIENCES ne cancerguard 79

  80. Slide 80: Increase access and drive adoption

    Everett Cunningham Chief Commercial Officer Increase access and drive adoption 808EXACT SCIENCES

  81. Slide 81: Strategic priorities

    Provide a seamless experience for customers Invest in world-class talent dedicated to fighting cancer Offer tests that impact decision-making Increase access & drive adoption Generate rock-solid clinical evidence Drive profitable revenue 81EXACT SCIENCES

  82. Slide 82: 1,200 person commercial organization

    1,200 person commercial organization Field team Health technology Provider marketing Market access Health systems Consumer marketing Medical geneticists 1,000 person field team Primary care Women’s health Gastro- enterology International oncology Oncology Surgeons Source: Exact Sciences internal dat

  83. Slide 83: The most powerful commercial engine in diagnostics

    The most powerful commercial engine in diagnostics 780 in-network agreements 370K cumulative providers have ordered brand awareness 85% 60 biopharma partnerships electronic connections 275 PAYERSHEALTH CARE PROFESSIONALS PATIENTS PHARMAHEALTH SYSTEMS Source: Exact Sciences internal data 83EXACT SCIE

  84. Slide 84: All-encompassing sales and marketing strategy

    Deploying an all-encompassing sales and marketing strategy Educating health care professionals Health systems and payer relationships Surround sound marketing 848EXACT SCIENCES

  85. Slide 85: Educating health care professionals

    85 1.6M+ FIELD CALLS EACH YEAR Source: Exact Sciences internal data EDUCATING HEALTH CARE PROFESSIONALS 8EXACT SCIENCES

  86. Slide 86: Educating health care professionals

    Educating health care professionals Data-driven insights promote agility and consistency EDUCATING HEALTH CARE PROFESSIONALS 86EXACT SCIENCES

  87. Slide 87: Educating health care professionals

    EDUCATING HEALTH CARE PROFESSIONALS 87EXACT SCIENCES

  88. Slide 88: Health system and payer relationships

    88 400 largest U.S. health systems 85 strategic account managers 60 oncology centers and integrated delivery networks Health technology solutions Targets Source: Exact Sciences internal data HEALTH SYSTEM & PAYER RELATIONSHIPS 8EXACT SCIENCES

  89. Slide 89: Health system and payer relationships

    90% of 21K unscreened people being ordered a Cologuard Cologuard auto ordered for cancelled or no-show colonoscopies INFORMATION TECHNOLOGY SUPPORT Source: Exact Sciences internal data HEALTH SYSTEM & PAYER RELATIONSHIPS 89EXACT SCIENCES

  90. Slide 90: Surround sound marketing

    90 Sizzle reel video SURROUND SOUND MARKETING 90EXACT SCIENCES

  91. Slide 91: Surround sound marketing

    SEARCH HCP CHANNELS SOCIAL RADIO TRADITIONAL VIDEO VIDEO STREAMING 10B+ advertisement impressions each year Source: Exact Sciences internal data SURROUND SOUND MARKETING 91EXACT SCIENCES

  92. Slide 92: Optimizing spend as revenue grows

    Optimizing spend as revenue grows 63% 50% 35% 52% 44% 55% 58%112% 2023E is midpoint of Exact Sciences guidance provided on May 9, 2023 92EXACT SCIENCES $99M $266M $454M $876M $1.49B $1.77B $2.08B $2.40B 2016 2017 2018 2019 2020 2021 2022 2023E Total revenue Sales & marketing expense 49% 41% 40% 44%

  93. Slide 93: Provide seamless experience

    Everett Cunningham Chief Commercial Officer Provide seamless experience 93EXACT SCIENCES

  94. Slide 94: Strategic priorities

    Provide a seamless experience for customers Invest in world-class talent dedicated to fighting cancer Offer tests that impact decision-making Increase access & drive adoption Generate rock-solid clinical evidence Drive profitable revenue 94EXACT SCIENCES

  95. Slide 95: We offer great services

    e don’t just have great tests, we offer great services 95EXACT SCIENCES

  96. Slide 96: 15M+ patient calls each year

    15M+ patient calls each year 75%+ enabled by technology Source: Exact Sciences internal data 96EXACT SCIENCES

  97. Slide 97: Investing in a seamless customer experience

    $62M $87M $113M $131M Customer experience Customer support team Test volume Investing in a seamless customer experience 2021 2022 2023E2020 Source: Exact Sciences internal data 97EXACT SCIENCES

  98. Slide 98: Perfecting the customer experience

    We have been working to perfect the customer experience for nearly a decade 220+ experiments conducted Source: Exact Sciences internal data 98EXACT SCIENCES

  99. Slide 99: Cologuard kit return app

    doubled completion rate of schedule UPS pickup feature 3 min → 30 seconds amount of time to complete task 8 min→5.5 min total app time Cologuard kit return “app” improving ease of use Source: Exact Sciences internal data 99EXACT SCIENCES

  100. Slide 100: Challenges in cancer care

    AWARENESS SCREENING DIAGNOSIS RX SELECTION & MONITORING MAINTENANCE Difficult to track patients who need screening Leave EMR to order tests Ambiguous imaging creates difficult next- step decision Implications of genetic testing confusing, hard to explain Unsure which treatment to use with too many o

  101. Slide 101: Seamless experience across the care journey

    Waiting for answers until follow-up visit; anxious about having cancer AWARENESS SCREENING DIAGNOSIS RX SELECTION & MONITORING MAINTENANCE Provide list of patients eligible for screening Order EXAS test directly in EMR Help patient comply; provider tracks test completion Provide diagnostic/ prognost

  102. Slide 102: Drive profitable revenue

    EXACT SCIENCES Jeff Elliott Chief Financial Officer Drive profitable revenue 102T SCIENCES

  103. Slide 103: Strategic priorities

    Provide a seamless experience for customers Invest in world-class talent dedicated to fighting cancer Offer tests that impact decision-making Increase access & drive adoption Generate rock-solid clinical evidence Drive profitable revenue 103EXACT SCIENCES

  104. Slide 104: Grow the core, increase profits, allocate capital

    EXACT SCIENCES Grow the core business Increase profits and cash flow Allocate capital 104T SCIENCES

  105. Slide 105: Q1 was a record-breaking quarter

    EXACT SCIENCES $450M $598M 1Q22 1Q23 ($90M) $46M 1Q22 1Q23 ($207M) ($68M) 1Q22 1Q23 72.3% 74.0% 1Q22 1Q23 Adjusted EBITDA Free cash flowNon-GAAP gross marginCore revenue +33% +1.7 pts +$136M +$140M Q1 was a record-breaking quarter Please refer to the appendix accompanying this presentation for discu

  106. Slide 106: Financial targets

    EXACT SCIENCES ~15% compounded annual revenue growth 2022-2027 (excluding COVID and prostate) 20%+ adjusted EBITDA margin in 2027 FINANCIAL TARGETS Note: compounded annual revenue growth based on total revenue in 2022, excluding revenue generated from COVID-19 testing and the divested Oncotype prost

  107. Slide 107: Screening revenue

    EXACT SCIENCES $39M $99M $266M $454M $810M $815M $1.06B $1.42B $1.78B 2015 2016 2017 2018 2019 2020 2021 2022 2023E Screening revenue 8-year CAGR: 60%+ Growth drivers Commercial productivity Rescreens Health system connections 45-49 age group CAGR revenue calculated using GAAP figures; 2023E is midp

  108. Slide 108: Precision Oncology revenue

    EXACT SCIENCES $394M $456M $440M $562M $601M $613M 2018 2019 2020 2021 2022 2023E 5-year CAGR: 9% Precision Oncology revenue Growth drivers Therapy selection International expansion Biopharma partnerships Node-positive adoption CAGR revenue calculated using GAAP figures; 2023E is midpoint of guidanc

  109. Slide 109: Non-GAAP gross profit and margin

    EXACT SCIENCES $15M $54M $188M $338M $660M $1.14B $1.31B $1.51B $1.75B 2015 2016 2017 2018 2019 2020 2021 2022 2023E Non-GAAP gross profit 73%+ Non-GAAP gross margin 8-year CAGR: 80%+ Key drivers Rescreen mix increasing Volume leverage Next-generation Cologuard Automation projects 2023E is midpoint

  110. Slide 110: Adjusted EBITDA

    EXACT SCIENCES ($90M) ($46M) ($13M) $5M $46M 1Q22 2Q22 3Q22 4Q22 1Q23 Adjusted EBITDA grew $136M Y/Y 2023 guidance 2027 target 5% 20% Expect adjusted EBITDA margin to increase 15 pts by 2027 2023 guidance for adjusted EBITDA margin refers to midpoint of guidance provided on May 9, 2023; Please refer

  111. Slide 111: Rescreen compliance and eligible population

    EXACT SCIENCES ~30 pt ~20 pt higher compliance for 2nd rescreen higher compliance for 1st rescreen Source: Exact Sciences internal data based on 90-day adherence rates 0.8M 1.3M 1.3M 1.7M 2.0M 0.1M 0.3M 0.4M 2021 2022 2023E 2024E 2025E Eligible for second rescreen Eligible for first rescreen INCREAS

  112. Slide 112: Path to positive free cash flow

    EXACT SCIENCES ($124M) ($86M) ($21M) ($68M) 2Q22 3Q22 4Q22 1Q23 2Q23E Positive Free cash flow Please refer to the appendix accompanying this presentation for discussion of non-GAAP financial measures and reconciliations to GAAP financial measures INCREASE PROFITS & CASH FLOW 112T SCIENCES

  113. Slide 113: Disciplined capital allocation

    EXACT SCIENCES Core business Pipeline opportunities Retaining cash flow Disciplined capital allocation ALLOCATE CAPITAL 113T SCIENCES

  114. Slide 114: Decrease in DSOs and claim errors

    EXACT SCIENCES 20 25 30 35 40 45 50 Jan 22 Mar 22 May 22 Jul 22 Sep 22 Nov 22 Jan 23 Mar 23 20-day decrease in DSOs 0K 5K 10K 15K 20K 25K 30K 35K Jan 22 Mar 22 May 22 Jul 22 Sep 22 Nov 22 Jan 23 Mar 23 99% decrease in Cologuard claim errors Source: Exact Sciences internal data ALLOCATE CAPITAL 114T

  115. Slide 115: Enhancing our state-of-the-art labs

    EXACT SCIENCES $200M cumulative cost savings expected by 2030 Enhancing our state-of-the-art labs ALLOCATE CAPITAL 115T SCIENCES

  116. Slide 116: Market size and penetration

    116 Total market penetration 20%0% 40% 60% 80% 100% Market size ($) Source: U.S. Census data and Exact Sciences estimates; U.S. markets only Esophageal Therapy selection Breast MCED $25B CRC $18BMRD $15B Liver Hereditary cancer testing Lung Thyroid Pancreatic Rare disease ALLOCATE CAPITAL 116EXACT S

  117. Slide 117: Peer comparison with Dx group

    EXACT SCIENCES $1.75B $230M 1 2 $316M $44M 1 2 Dx group average ~7x incremental revenue growth Dx group average ~8x non-GAAP gross profit dollars Source: Exact Sciences guidance provided May 9, 2023; FactSet Dx group includes 23andMe, Adaptive, GeneDX, Guardant Health, Invitae, Myriad, Natera, NeoGe

  118. Slide 118: Q&A session

    EXACT SCIENCES Q&A session 118T SCIENCES

  119. Slide 119: Expert health care professional panel

    EXACT SCIENCES Expert health care professional panel Charles Geyer MD, FACP Chief Scientific Officer, NSABP Foundation Professor of Medicine, UPMC Hillman Cancer Center Lisa Ravindra MD, FACP Assistant Professor of Medicine, Division of General Internal Medicine Associate Chief Medical Informatics O

  120. Slide 120: EXACT SCIENCES 120T

    EXACT SCIENCES 120 120T SCIENCES

  121. Slide 121: Powerful innovator and growth engine

    EXACT SCIENCES Exact Sciences is a powerful innovator and growth engine our team powers our flywheel best-in-class scientific capabilities profitable growth for years to come 121

  122. Slide 122: We aim to eradicate cancer

    EXACT SCIENCES We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment. 122EXACT SCIENCES

  123. Slide 123: Non-GAAP financial measures

    EXACT SCIENCES In addition to the company's financial results determined in accordance with U.S. GAAP, the company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. The company presents EBITDA, adjusted EBITDA, non-GAAP gross margin, no

  124. Slide 124: EBITDA and Adjusted EBITDA reconciliations

    EXACT SCIENCESEXACT SCIENCES 124 EXACT SCIENCES CORPORATION Selected Unaudited Financial Information EBITDA and Adjusted EBITDA Reconciliations (Amounts in thousands) (1) Interest expense (income) for the three months ended March 31, 2023, includes a $10.3 million net gain recorded on the settlement

  125. Slide 125: Non-GAAP gross profit and margin reconciliation

    EXACT SCIENCESEXACT SCIENCES 125 EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations (Amounts in thousands) (1) Includes only amortization of intangible assets identified as developed technology assets through purchase a

  126. Slide 126: Non-GAAP gross profit and margin reconciliation, annual

    EXACT SCIENCESEXACT SCIENCES 126 EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations (Amounts in thousands) (1) Includes only amortization of intangible assets identified as developed technology assets through purchase a

  127. Slide 127: Reconciliation of core revenue

    EXACT SCIENCESEXACT SCIENCES 127 EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of Core Revenue (Amounts in thousands) (1) Excludes revenue from the divested Oncotype DX Genomic Prostate Score test and COVID-19 testing. (2) Foreign currency impact is calculating t

  128. Slide 128: Cash flows and free cash flow reconciliation

    EXACT SCIENCESEXACT SCIENCES 128 EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow (Amounts in thousands) 1Q22 2Q22 3Q22 4Q22 1Q23 Net cash provided by (used in) operating activities $ (173,754) $

Exact Sciences — Investor Day (June 2023) on 6ix